Shares of Fortis Healthcare are likely to remain in focus on Monday after the hospital chain reported strong fourth-quarter earnings for FY26, supported by higher patient volumes, improved occupancy levels, and steady growth across its healthcare businesses.
The company delivered healthy year-on-year growth in revenue, operating profit, and net profit during the March quarter, reflecting improved operational efficiency and strong demand across key hospital and diagnostic segments.
Fortis Healthcare Q4 FY26 Results
Fortis Healthcare posted a consolidated net profit of Rs 266 crore in Q4 FY26, registering a sharp 44.6% increase compared to Rs 184 crore reported in the same quarter last year.
Revenue from operations rose 17.8% year-on-year to Rs 2,365 crore against Rs 2,007 crore in the corresponding quarter of the previous financial year. The growth was mainly driven by strong performance across hospital operations and diagnostic services.
At the operating level, EBITDA climbed 22.2% to Rs 532.3 crore in the March quarter, compared to Rs 435.4 crore a year ago. EBITDA margin improved to 22.5% from 21.7% in the year-ago period, indicating better cost management and improved operating leverage.
Fortis Healthcare share price Performance
Fortis Healthcare shares closed at Rs 960.40 on Friday, up 0.71% from the previous close of Rs 967.30.
During the trading session, the stock touched an intraday high of Rs 975.00 and a low of Rs 949.20. The stock has recorded a 52-week high of Rs 1,104.30, while the 52-week low stands at Rs 671.50.
Disclaimer: Investments in securities markets are subject to market risks. Read all related documents carefully before investing. The information provided is for educational and informational purposes only and should not be considered financial advice. Stock market investments can fluctuate based on market conditions, company performance, and economic factors. Past performance is not indicative of future returns. Always consult a qualified financial advisor before making any investment decisions. Neither the author nor the publisher is responsible for any financial losses incurred.